1. Scrip
  2. >>Business

Pharming Adds CDZ173 To Its Rare Disease Pipeline, Foresees Launch by 2022

 
• By Sten Stovall

The Dutch rare disease group says licensing CDZ173 from Novartis is Pharming’s first step towards building off the commercial success of its sole product, Ruconest, in HAE.

Add_To_Cart
CDZ173 is in late-stage trials for treating APDS • Source: Shutterstock

The Dutch rare disease company Pharming Group NV has embarked on expansion by acquiring an exclusive global license to CDZ173 (leniolisib), a late-stage small-molecule drug for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), a primary immune deficiency, in return for an upfront payment of $20m to Novartis AG as well as potential milestone and royalty payments.

CDZ173 is currently in a pivotal Phase II/III clinical trial as a treatment for APDS. Novartis has completed all the...

More from Business

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.